Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on staff interview and clinical record review, the facility staff failed to ensure 9 of 26 Residents were free of unnecessary medications. Residents #66, #89, #90, #100, #21, #28, #33, #59, #42.
The findings included:
1. For Resident #66, staff failed to ensure the resident received an anti-psychotic medication only to treat specific conditions and symptoms as documented in the clinical record.
Resident #66 was admitted to the facility on [DATE] with diagnoses including muscle weakness, dysphagia, dementia in other diseases classified elsewhere without behavioral disturbance, cerebral infarction due to embolism of other cerebral artery, type II diabetes mellitus without complications, essential primary hypertension, other specified anxiety disorders, major depressive disorders, insomnia, and chest pain. On the quarterly minimum data set assessment with assessment reference date 9/17/18, the resident scored 15/15 on the brief interview for mental status and was assessed as without symptoms of delirium, psychosis, or behaviors affecting care. The resident's medication assessment was coded under Medications received (N0410 A) as receiving anti-psychotic medications 7 of the 7 days prior to the assessment. Under Anti-psychotic Medication Review (0450), the resident was coded as not receiving anti-psychotic medications since admission or the prior assessment.
The resident's comprehensive care plan did not list dementia as a problem. No interventions under other care areas addressed symptoms of the resident's dementia. The comprehensive care plan did not address the resident's use of anti-psychotic medication or the symptoms and behaviors to be addressed by the anti-psychotic medication.
The surveyor asked the director of nursing for documentation of the symptoms for which the anti-psychotic Seroquel 100 milligram daily for anxiety with behaviors was being used along with documentation of the need for the anti-psychotic medication for anxiety rather than an anxiolytic medication.
Seroquel 100 mg daily was ordered 9/5/18 for anxiety with behaviors. There was no documentation of behavior symptoms. This was reportedly an increase to the prior dose after a gradual dose reduction attempt started 8/27/18. On 9/13/18, an administrative order for non-pharmacologic intervention codes for anxiety with behaviors was entered. No interventions were documented. An order to monitor for side effects associated with Seroquel documented no side effects.
Review of physician notes, psychiatric evaluations, and nursing progress notes revealed no documentation of the symptoms for which the resident was being treated with anti-psychotic medication. A nursing note dated 8/27/18 15:13 Resident continues to holler help, help. When staff asks resident what he needs his response varies: Can you move my covers, can you straighten my leg, can you pull me up. In no case after yelling help, help is the resident in any danger of falling off bed, no bleeding, no distress. Both he and his mother are very impatient when it comes to ADL(activity of daily living) care. The next note on 8/28/18 18:54 Resident turns light on shortly after receiving dinner tray staff feeding other residents and passing out trays when staff answers light resident state he is wet needing to be changed CNA told resident she would be back after taking cart to kitchen resident turns light back on before CNA can take cart to kitchen and come back. A note dated 9/2/18 18:39 Resident put on light at 1630 and 1715 stating he was wet CNA in both times resident was dry. No other notes concerning behavior or symptoms were documented before 9/5/18 17:09 FNP (family nurse practitioner) made aware that since Seroquel dosage change, resident has been experiencing increased anxiety and agitation. New orders received to restart previous dosage. The surveyor inferred that the behaviors for which the resident was being treated with an anti-psychotic medication were ringing the call bell when not bleeding or in danger of falling, and requesting help during meal times. No other behaviors or symptoms were documented by nursing or medical staff.
The resident was hospitalized after the initial brief contact on 10/16/18, so the surveyor was unable to complete the resident interview and assess for the use of chemical restraint for staff convenience.
The administrator, director of nursing and assistant director of nursing were notified of the concern during a summary meeting on 10/18/18.
5. The facility staff failed to identify and monitor resident specific targeted behaviors, identify non-pharmacological interventions, and monitor for effectiveness associated with the use of Abilify and Cymbalta for Resident #21.
The clinical record of Resident #21 was reviewed 10/16/18 through 10/18/18. Resident #21 was admitted to the facility 9/20/17 and readmitted [DATE] with diagnoses that included but not limited to Type 2 diabetes mellitus, symbolic dysfunction, dysphagia, repeated falls, cardiomyopathy, cerebellar stroke syndrome, alcohol-induced chronic pancreatitis, chronic pain syndrome, anemia, transient ischemic attacks, gastric diverticulum, altered mental status, Barrett's esophagus without dysplasia, hypertension, hemiplegia affecting left dormant side, bipolar disorder, anxiety disorder, atrial fibrillation, acute respiratory infection, viral hepatitis without hepatic coma, and cerebral infarction due to embolism.
Resident #21's quarterly minimum data set (MDS) with an assessment reference date (ARD) of 8/7/18 assessed the resident with a BIMS (brief interview for mental status) as 15/15. Resident #21 was assessed to have inattention continuously present, no psychosis, and no behaviors that affected others.
Resident #21's current comprehensive care plan had the focus area that read the resident was at risk for adverse effects r/t (related to) psychoactive medication use: antidepressant for depression; antipsychotic for mood stabilizer. Interventions: Monitor for side effects: sedation, hypotension, EPS (extrapyramidal symptoms), anticholinergic sx (symptoms), H/A (headache), insomnia, anorexia, constipation. Monitor for effectiveness of medications, Report changes in behavior or mood state, report to physician any negative outcomes associated with use of psychoactive drug.
Resident #21's October 2018 physician orders included orders for Abilify 5 mg (milligrams) in the morning for mood disorder and Cymbalta delayed release capsule 60 mg in the morning for depression and pain.
The surveyor reviewed the October 2018 electronic medication administration records (eMARS) but was unable to locate any targeted behaviors the staff were monitoring for Abilify and Cymbalta. There were no completed behavior monitoring records.
The current comprehensive care plan did not include targeted behaviors for the use of Abilify and Cymbalta.
The surveyor informed the corporate registered nurse of the above concern with monitoring of Abilify and Cymbalta on 10/17/18 12:07 PM. The surveyor requested the October 2018 eMARS.
The surveyor informed the administrative staff of the above concern on 10/17/18 at 3:20 p.m. in the end of the day meeting.
The surveyor reviewed the facility policy titled Psychotropic Medication Documentation and Review on 10/18/18. The policy read in part A. Residents receiving psychotropic medication will have a Behavior/Intervention Monthly Flow Record (BFR) (Form 4.11) initiated on admission or whenever psychotropic meds are ordered.
No further information was provided prior to the exit conference on 10/18/18.
6. The facility staff failed to identify and monitor resident specific targeted behaviors, identify non-pharmacological interventions, and monitor for effectiveness associated with the use of Elavil for Resident #28.
The clinical record of Resident #28 was reviewed 10/16/18 through 10/18/18. Resident #28 was admitted to the facility 9/7/16 and readmitted [DATE] with diagnoses that included but not limited to symbolic dysfunction, dysphagia, right shoulder contracture, major depressive disorder, Type 2 diabetes mellitus, seizures, iron deficiency anemia, urine retention, anxiety disorder, moderate protein calorie malnutrition, peripheral vascular disease, gastroesophageal reflux disease, bradycardia, diabetic neuropathy, chronic pain syndrome, paraplegia, acute renal failure, gastritis, bacteremia, hyperkalemia, insomnia, and hypertension.
Resident #28's quarterly minimum data set (MDS) assessment with an assessment reference date (ARD) of 8/10/18 assessed the resident with a BIMS (brief interview for mental status) as 15 out of 15. Resident #28 was assessed without any signs or symptoms of delirium, psychosis or behaviors that affected others.
Resident #28's current comprehensive care plan was reviewed and a care plan had not been developed for psychotropic medication.
The October 2018 physician orders were reviewed. Resident #28 had orders for Elavil 25 mg (milligrams) (Amitriptyline HCL) 1 tablet by mouth at bedtime for antidepressant Start Date 8/13/18.
The surveyor reviewed the October 2018 electronic medication administration records (eMARS) and the October 2018 behavior monitoring records but found no evidence monitoring of Elavil had been done, no targeted behaviors identified or a care plan been developed for the use of the antidepressant.
The surveyor informed the unit manager registered nurse #1 on 10/17/18 10:33 AM. R.N. #1 stated the nurses were not monitoring antidepressants use. The unit manager R.N. #1 stated she was not aware antidepressants needed to be monitored.
The surveyor informed the administrative staff of the above concern during the end of the day meeting on 10/17/18 at 3:20 p.m.
The surveyor reviewed the facility policy titled Psychotropic Medication Documentation and Review on 10/18/18. The policy read in part A. Residents receiving psychotropic medication will have a Behavior/Intervention Monthly Flow Record (BFR) (Form 4.11) initiated on admission or whenever psychotropic meds are ordered.
No further information was provided prior to the exit conference on 10/18/18.
7. The facility staff failed to identify targeted behaviors for Zoloft and failed to monitor the behavior of Resident #33.
The clinical record of Resident #33 was reviewed 10/16/18 through 10/18/18. Resident #33 was admitted to the facility on [DATE] with diagnoses, that included but not limited to hypomagnesia, insomnia, chronic pain syndrome, dry eye syndrome, hypertension, chronic diastolic heart failure, lymphedema, acute frontal sinusitis, gastroesophageal reflux disease, urinary tract infection, left knee hemarthosis, right elbow contracture, major depressive disorder, nutritional deficiency, and dysthymic disorder.
Resident #33's significant change in minimum data set (MDS) with an assessment reference date (ARD) of 8/16/18 assessed the resident with a BIMS (brief interview for mental status) as 12 out of 15 in Section C. Resident #33 was assessed without signs or symptoms of delirium, psychosis, or behaviors that affected others.
Resident #33's current comprehensive care plan identified that the resident was at risk for adverse effects r/t (related to) psychoactive medication use: Depression, insomnia. At risk for falls and over sedation. Interventions: Monitor for effectiveness of medications, Report changes in behavior or mood state, report to physician any negative outcomes associated with use of psychoactive drug.
Resident #33's October 2018 physician's orders were reviewed. The physician order dated 9/28/18 read Zoloft tablet 100 mg (Sertraline HCL) 1 tablet by mouth one time a day for depression.
The surveyor reviewed the October 2018 electronic medication administration records (eMARS) but was unable to locate any behavior monitoring of Zoloft-no identified targeted behaviors and no side effect monitoring.
The surveyor informed the administrative staff of the concern with Resident #33's Zoloft monitoring in the end of the day meeting on 10/18/18 at 3:08 p.m.
No further information was provided prior to the exit conference on 10/18/18.
8. The facility staff failed to ensure the antidepressant medication Fluvoxamine used to treat specific symptoms or behaviors associated with a diagnosis requiring treatment by an antidepressant medication and to ensure monitoring of the symptoms for which the antidepressant medication was ordered for Resident #59. Resident # 59's clinical record did not document the symptoms which the antidepressant medication was to address. There was no ongoing behavior monitoring of a resident receiving antidepressant medications.
The clinical record of Resident #59 was reviewed 10/16/18 through 10/18/18. Resident #59 was admitted to the facility 8/12/17 and readmitted [DATE] with diagnoses that included but not limited to metabolic encephalopathy, severe sepsis with shock, dysphagia, neuromuscular dysfunction of the bladder, hypertension, atherosclerotic heart disease, obsessive compulsive personality disorder, rhabdomyolysis, end stage renal disease, anxiety disorder, mental disorder, repeated falls, hyperkalemia, urinary tract infection, Parkinson's disease, and major depressive disorder.
Resident #59's quarterly minimum data set (MDS) assessment with an assessment reference date (ARD) of 9/12/18 assessed the resident with a BIMS (brief interview for mental status) as 9/15. Resident #59 was assessed to have hallucinations, but no signs or symptoms of delirium or psychosis.
Resident #59's current comprehensive care plan identified the resident to be at risk for adverse effects r/t (related to) psychoactive medication use: antidepressant and antipsychotic Date initiated: 07/17/2018 Revision on: 09/21/2018. Interventions: Monitor for effectiveness of medications, Report changes in behavior or mood state, report to physician any negative outcomes associated with use of psychoactive drug.
Resident #59's October physician orders were reviewed. Resident #59 had an order for Fluvoxamine Maleate 100 mg tablet Give 200 mg by mouth in the evening related to Obsessive-Compulsive Disorder.
FLUVOXAMINE is an antidepressant. It is used to treat obsessive-compulsive disorder.
The surveyor reviewed the October 2018 electronic medication administration record but was unable to locate any behavior monitoring of Fluvoxamine-no identified targeted behaviors and no side effect monitoring.
The surveyor informed the administrative staff of the concern with Resident #59's Fluvoxamine monitoring in the end of the day meeting on 10/17/18 at 3:20 p.m.
No further information was provided prior to the exit conference on 10/18/18.
9. For Resident #42, the facility staff failed to monitor the Residents prozac.
The clinical record review revealed that Resident #42 had been admitted to the facility 05/20/16. Diagnoses included, but were not limited to, depressive disorder, anxiety disorder, chronic pain, gastro-esophageal reflux disease, and hypertension.
Section C (cognitive patterns) of the Residents quarterly MDS (minimum data set) assessment with an ARD (assessment reference date) of 08/24/18 included a BIMS (brief interview for mental status) summary score of 15 out of a possible 15 points. Section N (medications) was coded to indicate the Resident had received antidepressant medication.
The Residents comprehensive care plan included the focus area is on antidepressant therapy. Interventions were administer antidepressant med as prescribed by the physician and refer to psych services.
The Residents current POS (physician order summary) included an order for prozac 40 mg one time a day.
During the clinical record review, the surveyor was unable to locate any information that the facility were offering and/or providing any behavioral interventions or monitoring for any side effects of this medication until after the survey team began asking questions regarding other Residents in the survey sample.
On 10/18/18, the facility provided the surveyor with a copy of the Residents behavior monitoring and side effect monitoring forms for the medication prozac. These forms revealed that the facility began using these forms on night shift on 10/16/18.
The administrative staff were notified of the above during a meeting with the survey team on 10/18/18 at 3:08 p.m.
No further information regarding this issue was provided to the survey team prior to the exit conference.
2. The facility staff failed to monitor effectiveness and identify target behaviors associated with the use of Risperdal for Resident # 89.
Resident # 89 was an [AGE] year-old-female who was admitted to the facility on [DATE]. Diagnoses included but were not limited to: schizoaffective disorder, hypertension, bipolar disorder, and hypothyroidism.
The clinical record for Resident # 89 was reviewed on 10/16/18 at 4:14 pm. The most recent MDS assessment (minimum data set) was a quarterly assessment with an ARD date (assessment reference date) of 9/24/18. Section C of the MDS assesses cognitive patterns. In section C0500, the facility staff documented that Resident # 89 had a BIMS score (brief interview for mental status) of 10 out of 15, which indicated that Resident # 89's cognitive status was moderately impaired. Section N of the MDS assesses medications. In Section N0410, the facility staff documented that Resident # 89 received an antipsychotic medication for 7 days during the look back period for the 9/24/18 ARD.
The plan of care for Resident # 89 was reviewed and revised on 7/31/18. The facility staff documented a focus area for Resident # 89 as Resident # 89 uses psychotropic medications related to bipolar and schizoaffective disorder. Interventions included but were not limited to: Administer medications as ordered. Monitor/document for side effects and effectiveness. The surveyor did not locate any documented target behaviors associated with the use of Risperdal on the plan of care for Resident # 89.
Resident # 89 had a current order that was signed by the physician on 10/9/18 for Risperdal tablet 0.5 mg (milligram) Give 0.5 mg by mouth one time a day for schizoaffective disorder. The surveyor reviewed the medication administration record for Resident # 89 and did not locate any documentation of monitoring target behaviors or effectiveness for the physician ordered Risperdal.
On 10/16/18 at 4:33 pm, the surveyor interviewed CNA # 1 (certified nursing assistant). The surveyor asked CNA # 1 if Resident # 89 displayed any abnormal behaviors. CNA # 1 stated, No she is sweet as pie.
On 10/16/18 at 4:35 pm, the surveyor interviewed unit manager RN # 1 and asked if Resident # 89 displayed any abnormal behaviors. RN # 1 stated, She is sweet as pie. The surveyor asked RN # 1 what behaviors Resident # 89 displayed to warrant the administration of Risperdal. RN # 1 stated that Resident # 89 had been admitted on the medication and that she was not aware of what behaviors Resident # 89 displayed to warrant the use of Risperdal. RN # 1 reviewed the clinical record for Resident # 89 along with the surveyor and agreed that there were no documented target behaviors or monitoring for effectiveness for the physician ordered Risperdal for Resident # 89.
The facility policy on Psychotropic Medication Documentation and Review contained documentation that included but was not limited to:
. Procedure
A.
Residents receiving psychotropic medication will have a behavior /Intervention Monthly Flow Record (BFR) (Form 4.11) initiated on admission or whenever psychotropic meds are ordered.
a.
Each psychotropic medication will be entered on BFR.
b.
Resident specific behaviors related to medication use will be entered on BFR.
B.
Nurses will document on the following every shift:
a.
Number of behavior episodes
d. any side effect(s) observed.
On 10/17/18 at 4:00 pm, the administrative team was made aware of the findings as stated above.
No further information regarding this issue was provided to the survey team prior to the exit conference on 10/18/18.
3. The facility staff failed to monitor physician ordered Duloxetine for effectiveness for Resident # 90.
Resident # 90 was an [AGE] year-old female who was originally admitted to the facility on [DATE] with a readmission date of 3/5/18. Diagnoses included but were not limited to osteoarthritis, cellulitis of right lower limb, major depressive disorder, and non-pressure chronic ulcer of right lower leg.
The clinical record for Resident # 90 was reviewed on 10/17/18 at 9:51 am. The most recent MDS assessment (minimum data set) was a quarterly assessment with an ARD date (assessment reference date) of 9/28/18. Section C of the MDS assesses cognitive patterns. In Section C0500, the facility staff documented that Resident # 90 had a BIMS score (brief interview for mental status) of 12 out of 15 which indicated that Resident # 90's cognitive status was moderately impaired. Section N of the MDS assesses medications. In Section N0141, the facility staff documented that Resident # 90 had received antidepressant medication for 7 days during the look back period for the 9/28/18 ARD.
The plan of care for Resident # 90 was reviewed and revised on 8/28/18. The facility staff documented a focus area for Resident # 90 as, Resident # 90 uses psychotropic medications r/t (related to) dx (diagnosis) of depression. Interventions included but were not limited to: Administer medications as ordered. Monitor/document for side effects and effectiveness.
Resident # 90 had current orders that were initiated by the physician on 3/5/18. Orders included but were not limited to: Duloxetine 30 mg (milligram) Give 1 capsule by mouth one time a day related to major depressive disorder.
On 10/17/18 at 9:55 am, the surveyor reviewed Resident # 90's medication administration record for October 2018. The surveyor did not locate any monitoring for effectiveness for the physician ordered Duloxetine.
On 10/18/18 at 12:25 pm, the surveyor spoke with unit manager RN # 1 (registered nurse) and made her aware that there was no monitoring for effectiveness for the physician ordered Duloxetine for Resident # 90. RN # 1 stated that she would get it taken care of.
The facility policy on Psychotropic Medication Documentation and Review contained documentation that included but was not limited to:
. Procedure
C.
Residents receiving psychotropic medication will have a behavior /Intervention Monthly Flow Record (BFR) (Form 4.11) initiated on admission or whenever psychotropic meds are ordered.
c.
Each psychotropic medication will be entered on BFR.
d.
Resident specific behaviors related to medication use will be entered on BFR.
D.
Nurses will document on the following every shift:
b.
Number of behavior episodes
d. any side effect(s) observed.
On 10/18/18 at 3:00 pm, the administrative team was made aware of the findings as stated above.
No further information was provided to the survey team prior to the exit conference on 10/18/18.
4. The facility staff failed to monitor physician ordered Seroquel for effectiveness for Resident # 100.
Resident # 100 was a [AGE] year-old-female who was admitted to the facility on [DATE]. Diagnoses included but were not limited to: MRSA (methicillin-resistant staphylococcus aureus), Parkinson's disease, schizophrenia, and muscle weakness.
The clinical record for Resident # 100 was reviewed on 10/16/18 at 11:22 am. During the time of the survey, there was no completed MDS assessment (minimum data set) for Resident # 100.
The plan of care for Resident # 100 was reviewed and revised on 10/16/18. The facility staff documented a focus area for Resident # 100 as. Resident # 100 uses psychotropic medications r/t (related to) schizoaffective disorder. Interventions included but were not limited to: Administer medications as ordered. Monitor/document for side effects and effectiveness.
Resident # 100 had current orders that were initiated by the physician on 10/10/18. Orders included but were not limited to: Seroquel tablet 25 mg (milligram) Give 1 tablet by mouth two times a day for paranoid schizophrenia.
On 10/16/18 at 12:17 pm, the surveyor reviewed the medication administration record and nurse's notes for Resident # 100. The surveyor did not locate any documentation of monitoring for effectiveness for the physician ordered Seroquel for Resident # 100.
On 10/16/18 at 12:48 pm, the surveyor interviewed LPN # 2 (licensed practical nurse). The surveyor asked LPN # 2 where the nursing staff documented the effectiveness of psychotropic medications. LPN # 2 stated, We have a behavior grid and we document the behaviors on there. LPN # 2 reviewed the clinical record for the behavior grid and LPN # 2 stated, She doesn't have one.
The facility policy on Psychotropic Medication Documentation and Review contained documentation that included but was not limited to:
. Procedure
E.
Residents receiving psychotropic medication will have a behavior /Intervention Monthly Flow Record (BFR) (Form 4.11) initiated on admission or whenever psychotropic meds are ordered.
e.
Each psychotropic medication will be entered on BFR.
f.
Resident specific behaviors related to medication use will be entered on BFR.
F.
Nurses will document on the following every shift:
c.
Number of behavior episodes
d. any side effect(s) observed.
On 10/17/18 at 4:00 pm, the administrative team was made aware of the findings as stated above.
No further information regarding this issue was provided to the survey team prior to the exit conference on 10/18/18.